This filing confirms ARCH Venture's large pre-IPO position in City Therapeutics. Monitor for the company's IPO filing (S-1) to assess valuation and potential lock-up terms. The conversion of preferred stock upon IPO will determine the public float and insider ownership dynamics.
Price Chart
Executive Summary
ARCH Venture Fund XII, L.P. and related parties filed initial statements of beneficial ownership (Form 3) for City Therapeutics, Inc., disclosing aggregate beneficial ownership of approximately 13.5 million shares of common stock (including shares issuable upon conversion of preferred stock). This is a routine filing required upon becoming a 10%+ holder or insider, indicating ARCH's significant pre-IPO stake in the company.
Key Facts
- ARCH Venture Fund XII, L.P. beneficially owns 2,718,292 shares of Common Stock directly.
- ARCH Venture Fund XII, L.P. also holds 3,294,900 shares of Common Stock issuable upon conversion of Series Seed convertible preferred stock.
- ARCH Venture Fund XII, L.P. holds 5,482,309 shares of Common Stock issuable upon conversion of Series A convertible preferred stock.
- ARCH Venture Fund XII, L.P. holds 2,027,006 shares of Common Stock issuable upon conversion of Series B convertible preferred stock.
- Total common stock equivalent held by ARCH Venture Fund XII, L.P. is approximately 13,522,507 shares.
- Preferred stock (Series Seed, Series A, Series B) converts to Common Stock on a 1-to-1.0983 basis and will convert automatically upon closing of the Issuer's initial public offering.
- Reporting persons include ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Partners XII, LLC, and individuals Keith Crandell, Kristina Burow, and Steven Gillis.
Financial Impact
ARCH Venture Fund XII, L.P. holds approximately 13.5 million common-equivalent shares, representing a substantial pre-IPO stake. No dollar value disclosed.
Risk Factors
- No financial data or business updates provided in this filing.
- Large insider stake may lead to overhang concerns post-IPO if lock-up expires.
- No information on company's pipeline, revenue, or stage of development.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001104659-26-116360 |
| Document: 0001104659-26-116360-index.html | 0001104659-26-116360 |
| Document: 0001104659-26-116360.txt | 0001104659-26-116360 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | SC 13D | $20.79 | awaiting T+1 | — | $21.26 (+2.26%) |
Oct 26, 2026 today | SC 13G | $20.79 | awaiting T+1 | — | $21.26 (+2.26%) |
Oct 22, 2026 4d ago | SC 13G | $20.77 $20.77 | · 0.00% | ▲ +0.52% | $21.26 (+2.36%) |
Oct 19, 2026 7d ago | Insider Cluster | $20.83 $20.43 | ▼ −1.92% | ▼ −2.45% | $21.26 (+2.06%) |
Oct 19, 2026 7d ago | Press Release | $20.83 $20.43 | ▼ −1.92% | ▼ −2.45% | $21.26 (+2.06%) |
Oct 16, 2026 10d ago | 424B4 | $21.46 $20.83 | ▼ −2.94% | ▼ −3.27% | $21.26 (−0.93%) |
Oct 16, 2026 11d ago | EFFECT | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $21.26 (−5.09%) |
Oct 15, 2026 11d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $21.26 (−5.09%) |
Oct 15, 2026 11d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $21.26 (−5.09%) |
Oct 15, 2026 11d ago | 3 | $22.40 $21.46 | ▼ −4.20% | ▼ −4.62% | $21.26 (−5.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers